BioCentury | Apr 12, 2019
Company News

FDA approves ViiV's two-drug HIV regimen

...see "ViiV Seeks FDA Approval for Two-Drug HIV-1 Regimen" ). ViiV markets Tivicay dolutegravir, an HIV integrase...
...LSE:GSK; NYSE:GSK), Pfizer Inc. (NYSE:PFE) and Shionogi & Co. Ltd. (Tokyo:4507). Sandi Wong, Staff Writer dolutegravir/lamivudine ViiV Healthcare Ltd. HIV integrase HIV...
BioCentury | Mar 15, 2019
Clinical News

ViiV planning submissions this year for two-drug HIV regimen

...with other antiretroviral agents. ViiV’s Triumeq is a once-daily tablet that comprises Tivicay dolutegravir, an HIV integrase...
...Editor cabotegravir (GSK1265744, s/gsk1265744, s-1265744) Edurant, rilpivirine (TMC278) GlaxoSmithKline plc Johnson & Johnson Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. DNA polymerase HIV integrase HIV/AIDS Conference...
BioCentury | Nov 2, 2018
Clinical News

ViiV's two-drug HIV regimen meets again in Phase III

...with other antiretroviral agents. ViiV’s Triumeq is a once-daily tablet that comprises Tivicay dolutegravir, an HIV integrase...
...Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Edurant rilpivirine; Cabotegravir Business: Infectious Molecular target: DNA polymerase; HIV integrase...
...rilpivirine (TMC278) Triumec, Triumeq, dolutegravir/abacavir/lamivudine (S-349572/S-265744/S-247303, 572-trii) GlaxoSmithKline plc Johnson & Johnson Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. DNA polymerase HIV integrase...
BioCentury | Oct 26, 2018
Clinical News

ViiV seeks FDA approval for two-drug HIV-1 regimen

...Phase III Primary Endpoint Data for Two-Drug HIV Regimen" ). ViiV markets Tivicay dolutegravir, an HIV integrase...
...& Co. Ltd. (Tokyo:4507). ViiV Healthcare Ltd., Brentford, U.K. Product: Dolutegravir/lamivudine Business: Infectious Jennie Walters dolutegravir/lamivudine ViiV Healthcare Ltd. HIV integrase HIV...
BioCentury | Aug 17, 2018
Clinical News

J&J, ViiV's two-drug regimen meets in Phase III for maintenance treatment of HIV-1 infection

...Co. Ltd. (Tokyo:4507), Osaka, Japan Product: Edurant rilpivirine; Cabotegravir Business: Infectious Molecular target: DNA polymerase; HIV integrase...
...III data (2H18) Chris Lieu cabotegravir (GSK1265744, s/gsk1265744, s-1265744) Edurant, rilpivirine (TMC278) Johnson & Johnson Shionogi & Co. Ltd. ViiV Healthcare Ltd. HIV integrase HIV/AIDS...
BioCentury | Jul 27, 2018
Clinical News

ViiV presents detailed Phase III primary endpoint data for two-drug HIV regimen

...to submit regulatory applications for the two-drug regimen this year. ViiV markets Tivicay dolutegravir, an HIV integrase...
...Product: Dolutegravir/lamivudine Business: Infectious Molecular target: HIV integrase; HIV reverse transcriptase Description: Combination of dolutegravir, an HIV integrase...
...compound #), dolutegravir (Generic), Tivicay (Other), 1349572 (Other) Truvada, emtricitabine/tenofovir GlaxoSmithKline plc Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. HIV integrase HIV...
BioCentury | Jun 15, 2018
Clinical News

ViiV's two-drug HIV regimen meets in Phase III for HIV

...present full data from the trials at a scientific meeting. ViiV markets Tivicay dolutegravir, an HIV integrase...
...Product: Dolutegravir/lamivudine Business: Infectious Molecular target: HIV integrase; HIV reverse transcriptase Description: Combination of dolutegravir, an HIV integrase...
...compound #), dolutegravir (Generic), Tivicay (Other), 1349572 (Other) Truvada, emtricitabine/tenofovir GlaxoSmithKline plc Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. HIV integrase HIV...
BioCentury | Jun 14, 2018
Clinical News

ViiV's two-drug HIV regimen meets in Phase III for HIV

...present full data from the trials at a scientific meeting. ViiV markets Tivicay dolutegravir, an HIV integrase...
...compound #), dolutegravir (Generic), Tivicay (Other), 1349572 (Other) Truvada, emtricitabine/tenofovir GlaxoSmithKline plc Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. HIV integrase HIV...
BioCentury | Jun 1, 2018
Clinical News

FDA issues MedWatch safety alert for dolutegravir

...dolutegravir is used at the time of conception and early in pregnancy. ViiV markets the HIV integrase...
BioCentury | May 25, 2018
Clinical News

ViiV, Janssen two-drug tablet approved in EU for HIV

...and said that the price has not yet been established. ViiV markets Tivicay dolutegravir, an HIV integrase...
...#), dolutegravir (Generic), Tivicay (Other), 1349572 (Other) GlaxoSmithKline plc Johnson & Johnson Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. HIV integrase...
Items per page:
1 - 10 of 265